The win ratio approach to analyzing composite outcomes: An application to the EVOLVE trial

Contemporary Clinical Trials

Volumn 48, Issue , 2016, Pages 119-124

  Abdalla, Safa ^a   Montez Rath, Maria E ^a   Parfrey, Patrick S ^b   Chertow, Glenn M ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Health Sciences Centre St John's   (Canada)

Author keywords

Cinacalcet; Composite endpoints; EVOLVE trial; Win ratio

Indexed keywords

CINACALCET; CALCIMIMETIC AGENT;

ARTICLE; CARDIOVASCULAR MORTALITY; CLINICAL TRIAL (TOPIC); FOLLOW UP; HEART INFARCTION; HOSPITALIZATION; METHODOLOGY; PROPORTIONAL HAZARDS MODEL; QUALITY OF LIFE; RANDOMIZATION; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; STRATIFIED SAMPLE; STUDY DESIGN; TIME TO EVENT ANALYSIS; UNSTABLE ANGINA PECTORIS; WIN RATIO METHOD; AGED; CAUSE OF DEATH; CHRONIC KIDNEY FAILURE; FEMALE; HEART FAILURE; HUMAN; MALE; MIDDLE AGED; MORTALITY; PERIPHERAL VASCULAR DISEASE; RANDOMIZED CONTROLLED TRIAL (TOPIC); STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME;

AGED; ANGINA, UNSTABLE; CALCIMIMETIC AGENTS; CAUSE OF DEATH; CINACALCET HYDROCHLORIDE; FEMALE; HEART FAILURE; HOSPITALIZATION; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; MORTALITY; MYOCARDIAL INFARCTION; PERIPHERAL VASCULAR DISEASES; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84973171112     PISSN: 15517144     EISSN: 15592030     Source Type: Journal    
DOI: 10.1016/j.cct.2016.04.001     Document Type: Article

References (19)

1. Inrig J.K., Califf R.M., Tasneem A., Vegunta R.K., Molina C., Stanifer J.W., et al. The landscape of clinical trials in nephrology: a systematic review of Clinicaltrials.gov. Am. J. Kidney Dis.: Off. J. Natl. Kidney Found. 2014, 63(5):771-780.
2. Montori V.M., Permanyer-Miralda G., Ferreira-Gonzalez I., Busse J.W., Pacheco-Huergo V., Bryant D., et al. Validity of composite end points in clinical trials. BMJ 2005, 330(7491):594-596.
3. Freemantle N., Calvert M., Wood J., Eastaugh J., Griffin C. Composite outcomes in randomized trials: greater precision but with greater uncertainty?. J. Am. Med. Assoc. 2003, 289(19):2554-2559.
4. Ferreira-González I., Permanyer-Miralda G., Domingo-Salvany A., Busse J.W., Heels-Ansdell D., Montori V.M., et al. Problems with use of composite end points in cardiovascular trials: systematic review of randomised controlled trials. BMJ 2007, 334(7597):786.
5. Armstrong P.W., Westerhout C.M., Van de Werf F., Califf R.M., Welsh R.C., Wilcox R.G., et al. Refining clinical trial composite outcomes: an application to the Assessment of the Safety and Efficacy of a New Thrombolytic-3 (ASSENT-3) trial. Am. Heart J. 2011, 161(5):848-854.
6. O'Brien P.C. Procedures for comparing samples with multiple endpoints. Biometrics 1984, 40(4):1079-1087.
7. Buyse M. Generalized pairwise comparisons of prioritized outcomes in the two-sample problem. Stat. Med. 2010, 29(30):3245-3257.
8. Rauch G., Rauch B., Schüler S., Kieser M. Opportunities and challenges of clinical trials in cardiology using composite primary endpoints. World J. Cardiol. 2015, 7(1):1-5.
9. Pocock S.J., Ariti C.A., Collier T.J., Wang D. The win ratio: a new approach to the analysis of composite endpoints in clinical trials based on clinical priorities. Eur. Heart J. 2012, 33(2):176-182.
10. Subherwal S., Anstrom K.J., Jones W.S., Felker M.G., Misra S., Conte M.S., et al. Use of alternative methodologies for evaluation of composite end points in trials of therapies for critical limb ischemia. Am. Heart J. 2012, 164(3):277-284.
11. Chertow G.M., Pupim L.B., Block G.A., Correa-Rotter R., Drueke T.B., Floege J., et al. Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events (EVOLVE): rationale and design overview. Clin. J. Am. Soc. Nephrol.: CJASN 2007, 2(5):898-905.
12. Chertow G.M., Correa-Rotter R., Block G.A., Drueke T.B., Floege J., Goodman W.G., et al. Baseline characteristics of subjects enrolled in the Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) trial. Nephrol. Dial. Transplant.: Off. Publ. Eur. Dial. Transplant Assoc.- Eur. Ren. Assoc. 2012, 27(7):2872-2879.
13. Chertow G.M., Block G.A., Correa-Rotter R., Drueke T.B., Floege J., Goodman W.G., et al. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N. Engl. J. Med. 2012, 367(26):2482-2494.
14. Briggs A.H., Parfrey P.S., Khan N., Tseng S., Dehmel B., Kubo Y., et al. Analyzing Health-Related Quality of Life in the EVOLVE trial: the joint impact of treatment and clinical events. Med. Decis. Making 2016, 10.1177/0272989X16638312.
15. Wei L.J., Lin D.Y., Weissfeld L. Regression analysis of multivariate incomplete failure time data by modeling marginal distributions. J. Am. Stat. Assoc. 1989, 84(408):1065-1073.
16. Finkelstein D.M., Schoenfeld D.A. Combining mortality and longitudinal measures in clinical trials. Stat. Med. 1999, 18(11):1341-1354.
17. Parfrey P.S., Drüeke T.B., Block G.A., Correa-Rotter R., Floege J., Herzog C.A., et al. The effects of cinacalcet in older and younger patients on hemodialysis: the Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) trial. Clin. J. Am. Soc. Nephrol.: CJASN 2015, 10(5):791-799.
18. Kosanske J., Bergstrahl E. Macro for greedy Matching Algorithm 2004, Mayo Clinic College of Medicine.
19. Anstrom K.J., Eisenstein E.L. From batting average to wins above replacement to composite end points-refining clinical research using baseball statistical methods. Am. Heart J. 2011, 161(5):805-806.